Resveratrol attenuates ischemia - reperfusion-induced leukocyte - endothelial cell adhesive interactions and prolongs allograft survival across the MHC barrier.
BACKGROUND
Ischemic - reperfusion (IR) injury is a multifactorial process that leads to tissue damage and rejection in composite tissue allotransplantation (CTA). Antioxidant or free radical scavenger may reduce IR injury, so the effects of resveratrol, a natural antioxidant, on amelioration of leukocyte - endothelial cell adhesive interaction and prevention of transplant rejection in CTA were investigated.


RESULTS
In a microcirculatory study, resveratrol significantly reduced the number of IR-induced leukocytes rolling, adhering, and transmigrating in the postcapillary venules of the cremaster muscle. In the CTA study using groin skin flap allotransplantation across the MHC barrier 8-11-week-old Brown Norway donors (RT1(n)) and 10-11-week-old Lewis recipients (RT1(l)) rats were randomized into 4 groups: isograft control, allograft control, and 2 groups that received different doses of resveratrol (0.1 or 0.5 mg/kg) for 7 days. Allograft control animals rejected their allograft between 5 and 7 days postoperatively, whereas resveratrol-treated recipients had a moderate survival prolongation compared with the allograft control group. Consistent with these observations, histology results also showed reduction of lymphocytic infiltration and necrosis in resveratrol-treated subjects.


CONCLUSIONS
Resveratrol treatment prolonged groin skin flap allotransplant survival in the recipient and ameliorated the leukocyte - endothelial cell adhesive interactions that may lead to attenuated and delayed rejection in CTA.
Hsieh
Yu-Hsuan
YH
Department of Life Science, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan.
Huang
Shiang-Suo
SS
Wei
Fu-Chan
FC
Hung
Li-Man
LM
D000818:Animals; D002448:Cell Adhesion / Q000187:drug effects*; D042783:Endothelial Cells / Q000473:pathology; D004730:Endothelium, Vascular / Q000473:pathology*; D006085:Graft Survival / Q000187:drug effects* / Q000276:immunology; D006648:Histocompatibility; D036904:Leukocyte Rolling / Q000187:drug effects; D007962:Leukocytes / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000473:pathology*; D000077185:Resveratrol; D016038:Skin Transplantation / Q000009:adverse effects / Q000276:immunology / Q000379:methods*; D013267:Stilbenes / Q000494:pharmacology*; D014184:Transplantation, Homologous; D014699:Venules / Q000473:pathology
D013267:Stilbenes; D000077185:Resveratrol